XC2 | Jotup

United Fire Group, Inc. Reports on Annual Meeting of Shareholders

Retrieved on:

Friday, May 21, 2021

Pursuant to this policy, on February 1, 2021, Jack B. Evans, Chairman of the Board of Directors, submitted his resignation as a director effective immediately following the Annual Meeting of Shareholders on May 19, 2021.

Key Points:

Pursuant to this policy, on February 1, 2021, Jack B. Evans, Chairman of the Board of Directors, submitted his resignation as a director effective immediately following the Annual Meeting of Shareholders on May 19, 2021.
He has served as a director since 1995 and as Vice Chairman from 1997 to 2009.
The Company thanks Mr. Evans for his many years of distinguished service to the Company and its community.
A.M. Best Company assigns a rating of "A" (Excellent) for members of the United Fire & Casualty Group.\nFor more information about UFG visit www.ufginsurance.com.\nPhotos accompanying this announcement\xc2\xa0are available at:\n'

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Emergent BioSolutions Inc. (EBS)

Retrieved on:

Friday, May 21, 2021

XC2, Emergent BioSolutions, Emergent, XE-class submarine

b'LOS ANGELES, May 21, 2021 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (\xe2\x80\x9cGPM\xe2\x80\x9d) reminds investors of the upcoming June 18, 2021 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Emergent BioSolutions Inc. (\xe2\x80\x9cEmergent\xe2\x80\x9d or the \xe2\x80\x9cCompany\xe2\x80\x9d) (NYSE: EBS ) common stock between April 24, 2020 and April 16, 2021, inclusive (the \xe2\x80\x9cClass Period\xe2\x80\x9d).\nIf you suffered a loss on your Emergent investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information at https://www.glancylaw.com/cases/emergent-biosolutions-inc/ .

Key Points:

b'LOS ANGELES, May 21, 2021 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (\xe2\x80\x9cGPM\xe2\x80\x9d) reminds investors of the upcoming June 18, 2021 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Emergent BioSolutions Inc. (\xe2\x80\x9cEmergent\xe2\x80\x9d or the \xe2\x80\x9cCompany\xe2\x80\x9d) (NYSE: EBS ) common stock between April 24, 2020 and April 16, 2021, inclusive (the \xe2\x80\x9cClass Period\xe2\x80\x9d).\nIf you suffered a loss on your Emergent investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information at https://www.glancylaw.com/cases/emergent-biosolutions-inc/ .
To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
If you wish to\xc2\xa0learn more\xc2\xa0about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact Charles Linehan, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to [email protected] , or visit our website at www.glancylaw.com .
If you inquire by email please include your mailing address, telephone number and number of shares purchased.\nThis press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.\nGlancy Prongay & Murray LLP, Los Angeles\n'

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Acadia Pharmaceuticals Inc. (ACAD)

Retrieved on:

Friday, May 21, 2021

Organic compounds, Chemical compounds, XC2, Pimavanserin, Toll-free telephone number, Shareholder, Class action, Chemistry

You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.\nAcadia is a biopharmaceutical company that develops a drug called pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia, as well as an adjunctive treatment for major depressive disorder.

Key Points:

You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.\nAcadia is a biopharmaceutical company that develops a drug called pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia, as well as an adjunctive treatment for major depressive disorder.
To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
If you wish to\xc2\xa0learn more\xc2\xa0about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact Charles Linehan, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to [email protected] , or visit our website at www.glancylaw.com .
If you inquire by email please include your mailing address, telephone number and number of shares purchased.\nThis press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.\nGlancy Prongay & Murray LLP, Los Angeles\n'

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Volkswagen AG (VWAGY)

Retrieved on:

Friday, May 21, 2021

XC2, Toll-free telephone number, Shareholder

You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.\nOn March 29, 2021, Volkswagen published a draft press release announcing its American subsidiaries\xe2\x80\x99 supposed name change to \xe2\x80\x9cVoltswagen.\xe2\x80\x9d Media outlets reported that they confirmed with the Company that the name change was real.

Key Points:

You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.\nOn March 29, 2021, Volkswagen published a draft press release announcing its American subsidiaries\xe2\x80\x99 supposed name change to \xe2\x80\x9cVoltswagen.\xe2\x80\x9d Media outlets reported that they confirmed with the Company that the name change was real.
To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
If you wish to\xc2\xa0learn more\xc2\xa0about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact Charles Linehan, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to [email protected] , or visit our website at www.glancylaw.com .
If you inquire by email please include your mailing address, telephone number and number of shares purchased.\nThis press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.\nGlancy Prongay & Murray LLP, Los Angeles\n'

Low inventory, high prices guide NYS housing market in April

Retrieved on:

Friday, May 21, 2021

XC2, National Association of Realtors

Amid the beginning of the COVID-19 pandemic in April 2020, inventory of units on the market was 49,195.

Key Points:

Amid the beginning of the COVID-19 pandemic in April 2020, inventory of units on the market was 49,195.
In April 2021, there were 38,751 homes available \xe2\x80\x93 a 22.2 percent decrease.\nThe median price of homes continued to climb, escalating to $370,000 in April 2021.
This represents an 42.3% increase from the $260,000 price in April 2020.
These REALTORS\xc2\xae are also members of the New York State Association of REALTORS\xc2\xae as well as their local board or association of REALTORS\xc2\xae.\n'

BioSig Technologies, Inc. to Present at the Oppenheimer MedTech, Tools & Diagnostics Summit

Retrieved on:

Friday, May 21, 2021

Branches of biology, Cardiac electrophysiology, Medtech, Zimmer Biomet Robotics, XC2, Electrophysiology, Branches of biology, Cardiac electrophysiology, Medtech, Zimmer Biomet Robotics, XC2, Electrophysiology

The presentation will be available from 8am EST \xe2\x80\x93 5pm EST \xc2\xa0on the conference website Oppenheimer MedTech, Tools, & Diagnostics Summit (wsw.com) .

Key Points:

The presentation will be available from 8am EST \xe2\x80\x93 5pm EST \xc2\xa0on the conference website Oppenheimer MedTech, Tools, & Diagnostics Summit (wsw.com) .
The Company will also be available for one-on-one investor meetings.\nBioSig\'s PURE EP(tm) System is an advanced signal acquisition and processing platform that sets a new standard in electrophysiology.
The system provides essential diagnostic signals with high clinical value in all types of cardiac ablations.
The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.\n'

HAGENS BERMAN Reminds PureCycle Technologies (PCT) Investors of Securities Class Action and Application Deadline, Encourages Investors with Losses to Contact the Firm

Retrieved on:

Friday, May 21, 2021

XC2, Whistleblower, Steve Berman, Articles, Human rights, Social issues

b'SAN FRANCISCO, May 21, 2021 (GLOBE NEWSWIRE) -- Hagens Berman urges PureCycle Technologies, Inc. (NASDAQ: PCT) investors with significant losses to submit your losses now .

Key Points:

b'SAN FRANCISCO, May 21, 2021 (GLOBE NEWSWIRE) -- Hagens Berman urges PureCycle Technologies, Inc. (NASDAQ: PCT) investors with significant losses to submit your losses now .
Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC.
The firm represents investors, whistleblowers, workers and consumers in complex litigation.\xc2\xa0\xc2\xa0 More about the firm and its successes is located at hbsslaw.com .
For the latest news visit our newsroom or follow us on Twitter at @classactionlaw .\n'

Janssen Receives Two Positive CHMP Opinions Recommending Expanded Use of DARZALEX®▼ (daratumumab) Subcutaneous (SC) Formulation for New Indications in Europe

Retrieved on:

Friday, May 21, 2021

Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical trials, Other Health, Drugs, Health sciences, Health, Orphan drugs, Breakthrough therapy, Daratumumab, Clinical endpoint, Progression-free survival, Amyloidosis, XC2, Daratumumab/hyaluronidase

The study includes 388 patients with newly diagnosed AL amyloidosis with measurable haematologic disease and one or more organs affected.

Key Points:

The study includes 388 patients with newly diagnosed AL amyloidosis with measurable haematologic disease and one or more organs affected.
The study, which was conducted in collaboration with the European Myeloma Network, enrolled 304 participants.10\nThe primary endpoint is progression-free survival (PFS) between treatment arms.
Secondary endpoints include rates of overall response rate (ORR), very good partial response (VGPR) or better, complete response (CR) or better and duration of response, among others.
European Commission Grants Marketing Authorisation for DARZALEX\xc2\xae\xe2\x96\xbc(Daratumumab) Subcutaneous Formulation for All Currently Approved Daratumumab Intravenous Formulation Indications.

Jack Nathan Health Announces Change in Senior Management

Retrieved on:

Friday, May 21, 2021

General Health, Health, Practice Management, Other Health, XC2, OTC Markets Group

b'Jack Nathan Medical Corp. (TSXV: JNH, OTCQB: JNHMF) ("Jack Nathan Health" or the "Company") announces that following a strategic review of the Company, the Board of Directors of the Company (the "Board") has terminated the employment of Mr. George Barakat as Chief Executive Officer of the Company and its subsidiaries.

Key Points:

b'Jack Nathan Medical Corp. (TSXV: JNH, OTCQB: JNHMF) ("Jack Nathan Health" or the "Company") announces that following a strategic review of the Company, the Board of Directors of the Company (the "Board") has terminated the employment of Mr. George Barakat as Chief Executive Officer of the Company and its subsidiaries.
Mike Marchelletta, Co-founder and President will assume the role of Interim Chief Executive Officer, effective immediately.
The Company is commencing a search process to identify a suitable successor to fill the role of Chief Executive Officer on a permanent basis.\nAbout Jack Nathan Medical Corp.\nJack Nathan Medical Corp., operating as Jack Nathan Health\xc2\xae, is one of Canada\xe2\x80\x99s largest healthcare networks.
The words "may", "would", "could", "should", "potential", "will", "seek", "intend", "plan", "anticipate", "believe", "estimate", "expect" and similar expressions as they relate to Jack Nathan are intended to identify forward-looking information.

Fiserv to Present at J.P. Morgan’s Global Technology, Media and Communications Conference

Retrieved on:

Friday, May 21, 2021

Professional services, Data management, Technology, Software, Finance, Networks, Banking, Service companies, Fiserv, Waukesha County, Wisconsin, Finance, XC2, NASDAQ, Companies

b"Fiserv, Inc. (NASDAQ: FISV), a leading global provider of payments and financial services technology solutions, announced today that Frank Bisignano, President and Chief Executive Officer, will present virtually at J.P. Morgan\xe2\x80\x99s Global Technology, Media and Communications Conference on May 25, 2021 at 10:15 a.m. ET.\nFiserv, Inc. (NASDAQ: FISV) aspires to move money and information in a way that moves the world.

Key Points:

b"Fiserv, Inc. (NASDAQ: FISV), a leading global provider of payments and financial services technology solutions, announced today that Frank Bisignano, President and Chief Executive Officer, will present virtually at J.P. Morgan\xe2\x80\x99s Global Technology, Media and Communications Conference on May 25, 2021 at 10:15 a.m. ET.\nFiserv, Inc. (NASDAQ: FISV) aspires to move money and information in a way that moves the world.
As a global leader in payments and financial technology, the company helps clients achieve best-in-class results through a commitment to innovation and excellence in areas including account processing and digital banking solutions; card issuer processing and network services; payments; e-commerce; merchant acquiring and processing; and the Clover\xc2\xae cloud-based point-of-sale solution.
Fiserv is a member of the S&P 500\xc2\xae Index and the FORTUNE\xc2\xae 500, and is among FORTUNE World's Most Admired Companies\xc2\xae.
Visit fiserv.com and follow on social media for more information and the latest company news.\n"